Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 4/20 | 0.45 |
| ▸ | METAP2 | P50579 | 3/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.37 |
| ▸ | PYGL | P06737 | 4/20 | 0.36 |
| ▸ | PYGM | P11217 | 4/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2287539 | 1.00 | METAP1 (0.45) | METAP1METAP2RIPK1PYGLPYGM | |
| SCHEMBL2281035 | 0.89 | METAP1 (0.56) | METAP1METAP2RIPK1PYGLPYGM | |
| SCHEMBL2286193 | 0.89 | METAP1 (0.56) | METAP1METAP2RIPK1PYGLPYGM | |
| SCHEMBL12376335 | 0.89 | METAP1 (0.56) | METAP1METAP2RIPK1PYGLPYGM | |
| SCHEMBL2286197 | 0.89 | METAP1 (0.56) | METAP1METAP2RIPK1PYGLPYGM | |
| SCHEMBL2281031 | 0.89 | METAP1 (0.56) | METAP1METAP2RIPK1PYGLPYGM | |
| SCHEMBL12345895 | 0.79 | METAP1 (0.41) | METAP1METAP2RIPK1 | |
| SCHEMBL2235045 | 0.79 | METAP1 (0.41) | METAP1METAP2RIPK1 | |
| SCHEMBL2235041 | 0.79 | METAP1 (0.41) | METAP1METAP2RIPK1 | |
| SCHEMBL13818349 | 0.78 | METAP1 (0.65) | METAP1METAP2RIPK1PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | claimed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | claimed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-04-16 | — | — | US | disclosed |
| WO-2007135293-A2 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099152-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | GABRA5, GABRA2, GABRA3 | METAP1 4009/4885METAP2 2493/4885RIPK1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.